Cantor Fitzgerald Analysts Give bluebird bio (BLUE) a $122.00 Price Target

Cantor Fitzgerald set a $122.00 price objective on bluebird bio (NASDAQ:BLUE) in a research note released on Friday. The brokerage currently has a hold rating on the biotechnology company’s stock.

Several other analysts have also recently commented on the stock. Svb Leerink cut shares of bluebird bio from an outperform rating to a market perform rating in a research note on Tuesday, March 5th. Leerink Swann cut shares of bluebird bio from an outperform rating to a market perform rating and set a $150.00 price target on the stock. in a research note on Tuesday, March 5th. They noted that the move was a valuation call. ValuEngine raised shares of bluebird bio from a hold rating to a buy rating in a research note on Friday, March 1st. Cowen began coverage on shares of bluebird bio in a research note on Tuesday, February 26th. They set an outperform rating and a $149.91 price target on the stock. Finally, SunTrust Banks decreased their price target on shares of bluebird bio to $184.00 and set a buy rating on the stock in a research note on Monday, February 25th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $168.12.

Shares of BLUE traded down $9.54 during mid-day trading on Friday, hitting $146.64. 522,375 shares of the company traded hands, compared to its average volume of 610,099. bluebird bio has a one year low of $87.49 and a one year high of $199.70. The stock has a market capitalization of $8.58 billion, a P/E ratio of -13.73 and a beta of 2.64.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.83) by $0.11. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. The business had revenue of $19.20 million for the quarter, compared to analysts’ expectations of $9.06 million. During the same period in the prior year, the firm earned ($2.52) earnings per share. bluebird bio’s revenue was up 357.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that bluebird bio will post -11.81 EPS for the current fiscal year.

In related news, insider Jeffrey T. Walsh sold 3,000 shares of the stock in a transaction that occurred on Wednesday, January 16th. The shares were sold at an average price of $125.14, for a total value of $375,420.00. Following the transaction, the insider now directly owns 35,483 shares in the company, valued at $4,440,342.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Nick Leschly sold 7,374 shares of the stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $113.64, for a total transaction of $837,981.36. Following the completion of the transaction, the insider now owns 20,682 shares in the company, valued at $2,350,302.48. The disclosure for this sale can be found here. Insiders sold 42,438 shares of company stock worth $5,486,744 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its holdings in bluebird bio by 1.0% in the fourth quarter. FMR LLC now owns 8,204,161 shares of the biotechnology company’s stock worth $813,853,000 after purchasing an additional 80,474 shares during the period. Capital Research Global Investors raised its holdings in bluebird bio by 8.1% in the third quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock worth $968,610,000 after purchasing an additional 494,787 shares during the period. Vanguard Group Inc. raised its holdings in bluebird bio by 10.1% in the third quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock worth $674,435,000 after purchasing an additional 422,866 shares during the period. Vanguard Group Inc raised its holdings in bluebird bio by 10.1% in the third quarter. Vanguard Group Inc now owns 4,619,413 shares of the biotechnology company’s stock worth $674,435,000 after purchasing an additional 422,866 shares during the period. Finally, Capital World Investors raised its holdings in bluebird bio by 37.4% in the third quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock worth $500,150,000 after purchasing an additional 931,932 shares during the period.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Recommended Story: What are municipal bonds?

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.